Monoclonal Antibodies Developed Against Colorectal Cancer

After additional characterization, the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.

MabCure, Inc. (New York, NY, USA) is the biotech company that developed the technology. "Colorectal cancer is a devastating disease that could be treated effectively if diagnosed at an early stage,” said Dr. Amnon Gonenne, MabCure's president and CEO. "Creating MAbs against CRC allows MabCure to explore its uses for diagnosis and imaging, producing tremendous value for our company and shareholders, complementing the work we are doing in ovarian and prostate cancers. Today's announcement is consistent with our focus on commercializing diagnostic tests in markets in which there is significant demand.”

All men and women 50 years and older should be screened for CRC, a leading cause of death for both sexes in nearly equal numbers. The company estimates the European and U.S. market potential to each be in the billion-dollar range.

Related Links:
MabCure